Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $217000.0.

  • Syndax Pharmaceuticals' Other Non-Current Assets changed 0.0% to $217000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $217000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $217000.0 for FY2024, which is 5313.17% down from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $217000.0 for Q3 2025, which was down 0.0% from $217000.0 recorded in Q2 2025.
  • Syndax Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $1.0 million during Q1 2022, with a 5-year trough of $115000.0 in Q1 2021.
  • Over the past 5 years, Syndax Pharmaceuticals' median Other Non-Current Assets value was $217000.0 (recorded in 2024), while the average stood at $423263.2.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Other Non-Current Assets plummeted by 9092.34% in 2021, and later soared by 79304.35% in 2022.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Other Non-Current Assets stood at $115000.0 in 2021, then soared by 601.74% to $807000.0 in 2022, then tumbled by 42.63% to $463000.0 in 2023, then tumbled by 53.13% to $217000.0 in 2024, then changed by 0.0% to $217000.0 in 2025.
  • Its last three reported values are $217000.0 in Q3 2025, $217000.0 for Q2 2025, and $217000.0 during Q1 2025.